Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06818656 · ClinicalTrials.gov registry record

The Unhide™ Project: Economic Impact Study of IVIG Treatment for PANS

A clinical trial, sponsored by Brain Inflammation Collaborative.

Completed
Registry status
65
Enrollment target

NCT06818656 is a clinical trial that has completed, run by Brain Inflammation Collaborative. The registered enrollment target is 65 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06818656 has completed, sponsored by Brain Inflammation Collaborative.

COMPLETED
Registry status
65 participants
Enrollment target

Study Summary

The Economic Impact Study of IVIG treatment for PANS is a part of the Unhide™ Project, which is a research initiative developed by the Brain Inflammation Collaborative. Specifically, the Unhide™ project is a collection of investigations with the overall goal of better understanding the problems with thinking and mood that can sometimes be symptoms of conditions like autoimmune disease, infection-associated chronic conditions like Long COVID, ME/CFS, PANDAS, PANS, and other illnesses. Your contribution to this research will allow us to better describe these symptoms and understand what causes them, how they develop, and how they can best be treated and prevented. This study seeks to assess how PANDAS/PANS affects the financial well-being of families who pursue IVIG treatment, as well as the overall health and quality of life of children with the condition. By gathering data through this survey, we aim to gain important insights into the economic consequences of treating - or not treating - PANS with IVIG, including how it impacts parents' ability to work and children's ability to attend school. Key Eligibility Criteria * Aged 2-89, U.S. resident, fluent in English, and have access to computer and/or smartphone * Suspected or confirmed diagnosis of PANS/PANDAS * Have received IVIG OR have sought and/or been prescribed IVIG but have not received it

Trial Details

FieldValue
Enrollment Target 65 participants
Start Date 2025-03-01
Est. Completion 2025-06-19

Sponsor

Brain Inflammation Collaborative

2 total trials

What the Registry Record Tells You About NCT06818656

The ClinicalTrials.gov registry entry for NCT06818656 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brain Inflammation Collaborative, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT06818656 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT06818656 about?

NCT06818656 is a clinical study titled "The Unhide™ Project: Economic Impact Study of IVIG Treatment for PANS". The Economic Impact Study of IVIG treatment for PANS is a part of the Unhide™ Project, which is a research initiative developed by the Brain Inflammation Collaborative. Specifically, the Unhide™ project is a collection of investigations with the overall goal of better understanding the problems with...

What is the current status of trial NCT06818656?

This trial is currently completed. The enrollment target is 65 participants. The study started on 2025-03-01. Estimated completion is 2025-06-19.

Who is sponsoring clinical trial NCT06818656?

This trial is sponsored by Brain Inflammation Collaborative, which has 2 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.